MA35245B1 - Pyridin-2-amides utiles comme agonistes de cb2 - Google Patents

Pyridin-2-amides utiles comme agonistes de cb2

Info

Publication number
MA35245B1
MA35245B1 MA36535A MA36535A MA35245B1 MA 35245 B1 MA35245 B1 MA 35245B1 MA 36535 A MA36535 A MA 36535A MA 36535 A MA36535 A MA 36535A MA 35245 B1 MA35245 B1 MA 35245B1
Authority
MA
Morocco
Prior art keywords
pyridin
agonists
amides useful
amides
useful
Prior art date
Application number
MA36535A
Other languages
English (en)
Inventor
Caterina Bissantz
Uwe Grether
Paul Hebeisen
Atsushi Kimbara
Qingping Liu
Matthias Nettekoven
Marco Prunotto
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Christoph Ullmer
Zhiwei Wang
Wulun Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA35245B1 publication Critical patent/MA35245B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)

Abstract

L'invention porte sur un composé de formule (i) dans laquelle r
MA36535A 2011-06-10 2013-12-06 Pyridin-2-amides utiles comme agonistes de cb2 MA35245B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011075606 2011-06-10
PCT/EP2012/060785 WO2012168350A1 (fr) 2011-06-10 2012-06-07 Pyridin-2-amides utiles comme agonistes de cb2

Publications (1)

Publication Number Publication Date
MA35245B1 true MA35245B1 (fr) 2014-07-03

Family

ID=46208600

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36535A MA35245B1 (fr) 2011-06-10 2013-12-06 Pyridin-2-amides utiles comme agonistes de cb2

Country Status (36)

Country Link
US (2) US9321727B2 (fr)
EP (2) EP3072886B1 (fr)
JP (3) JP5997265B2 (fr)
KR (1) KR20140042848A (fr)
CN (2) CN106349156B (fr)
AR (1) AR086881A1 (fr)
AU (2) AU2012266369B2 (fr)
BR (1) BR112013031463A2 (fr)
CA (1) CA2835745A1 (fr)
CL (1) CL2013003486A1 (fr)
CO (1) CO6811864A2 (fr)
CR (1) CR20130616A (fr)
CY (1) CY1117878T1 (fr)
DK (2) DK3072886T3 (fr)
EA (2) EA023287B1 (fr)
EC (1) ECSP13013074A (fr)
ES (2) ES2588327T3 (fr)
HK (1) HK1231465A1 (fr)
HR (2) HRP20161064T2 (fr)
HU (2) HUE037666T2 (fr)
IL (2) IL229685B (fr)
LT (1) LT3072886T (fr)
MA (1) MA35245B1 (fr)
MX (1) MX339992B (fr)
MY (1) MY184978A (fr)
PE (2) PE20141583A1 (fr)
PH (1) PH12016501375A1 (fr)
PL (2) PL3072886T3 (fr)
PT (2) PT2718266T (fr)
RS (2) RS57262B1 (fr)
SG (1) SG10201604687QA (fr)
SI (2) SI2718266T1 (fr)
TR (1) TR201808273T4 (fr)
TW (1) TWI567062B (fr)
UA (1) UA114087C2 (fr)
WO (1) WO2012168350A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
PT2928882T (pt) 2012-12-07 2017-03-16 Hoffmann La Roche Derivados de pirazina como agonistas do recetor de cb2
KR20150092232A (ko) 2012-12-07 2015-08-12 에프. 호프만-라 로슈 아게 Cb2 작용제로 유용한 피리딘-2-아마이드
KR20150091080A (ko) 2012-12-07 2015-08-07 에프. 호프만-라 로슈 아게 Cb2 작용제로서 유용한 피리딘-2-아마이드
PT2928881T (pt) * 2012-12-07 2018-05-07 Hoffmann La Roche Novos derivados de piridina
SI2964646T1 (sl) 2013-03-07 2017-08-31 F. Hoffmann-La Roche Ag Novi derivati pirazola
EA027569B1 (ru) * 2013-03-26 2017-08-31 Ф.Хоффманн-Ля Рош Аг Производные пиридина
SG11201509029PA (en) 2013-05-02 2015-12-30 Hoffmann La Roche Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
WO2014177490A1 (fr) 2013-05-02 2014-11-06 F. Hoffmann-La Roche Ag Dérivés de la purine en tant qu'agonistes du récepteur cb2
BR112016015449A8 (pt) * 2013-12-30 2020-06-09 Lifesci Pharmaceuticals Inc compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
MX2016012690A (es) * 2014-04-04 2017-04-27 Hoffmann La Roche Piridin-2-carboxamidas 5,6-disustituidas como agonistas del receptor cannabinoide.
WO2015150440A1 (fr) * 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag Pyridine-2-amides utiles comme agonistes de cb2
CN104004006B (zh) * 2014-05-15 2016-04-06 广州康瑞泰药业有限公司 一种3,6-二氢-2h-吡喃-4-硼酸频哪醇酯的合成方法
CN104003934B (zh) * 2014-06-13 2016-04-13 西华大学 6-氯-3-氟-2-吡啶甲酸的合成
GB201415569D0 (en) * 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
AU2016342027B2 (en) 2015-10-23 2021-05-13 Navitor Pharmaceuticals, Inc. Modulators of Sestrin-GATOR2 interaction and uses thereof
JP2019500330A (ja) * 2015-11-26 2019-01-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリパノソーマ抑制剤
EP3386951B1 (fr) * 2015-12-09 2020-02-26 H. Hoffnabb-La Roche Ag Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
EA036668B1 (ru) 2017-01-23 2020-12-07 Кадент Терапеутикс, Инк. Модуляторы калиевых каналов
JP7179015B2 (ja) 2017-04-26 2022-11-28 ナビター ファーマシューティカルズ， インコーポレイテッド Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用
EP3642200B1 (fr) 2017-06-20 2023-05-03 F. Hoffmann-La Roche AG Dérivés de pyridines
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
JP7454512B2 (ja) 2018-06-27 2024-03-22 エフ． ホフマン－ラ ロシュ アーゲー 優先的カンナビノイド２アゴニストとしてのピリジン及びピラジン誘導体
EP3814328A1 (fr) * 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Nouveaux composés de pyridine et de pyrazine substitués par azétidine en tant qu'inhibiteurs du récepteur cannabinoïde 2
BR112020025013A2 (pt) * 2018-06-27 2021-03-23 F. Hoffmann-La Roche Ag novos compostos de piridina e pirazina como inibidores do receptor 2 de canabinoide
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
CN113226466A (zh) 2018-10-22 2021-08-06 科登特治疗公司 钾通道调节剂的结晶形式
EP3870158A4 (fr) 2018-10-24 2022-08-10 Navitor Pharmaceuticals, Inc. Composés polymorphes et leurs utilisations
CN109665982B (zh) * 2019-01-22 2022-07-08 深圳市第二人民医院 奈非西坦中间体2-吡咯烷酮的合成方法
EP4051259A4 (fr) 2019-11-01 2023-11-22 Navitor Pharmaceuticals, Inc. Méthodes de traitement à l'aide d'un modulateur de mtorc1
IL296649A (en) * 2020-03-23 2022-11-01 Praxis Prec Medicines Inc kcnt1 inhibitors and methods of use
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
EP4359399A1 (fr) * 2021-06-24 2024-05-01 Reservoir Neuroscience, Inc. Composés antagonistes d'ep2
WO2023169984A1 (fr) * 2022-03-11 2023-09-14 Syngenta Crop Protection Ag Composés herbicides
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005965D0 (en) * 1990-03-16 1990-05-09 Shell Int Research Herbicidal carboxamide derivatives
GB9025828D0 (en) * 1990-11-28 1991-01-09 Shell Int Research Herbicidal carboxamide derivatives
ES2086579T3 (es) * 1991-05-31 1996-07-01 Sumitomo Pharma Antagonista de leucotrieno b4.
TW226012B (fr) * 1991-11-19 1994-07-01 Dunlena Pty Ltd
GB2277930A (en) 1993-05-11 1994-11-16 Shell Int Research Herbicidal picolinamide derivatives
EP1492784A4 (fr) * 2002-03-28 2006-03-29 Merck & Co Inc 2,3-diphenyl-pyridines substituees
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
PL374971A1 (en) 2002-08-09 2005-11-14 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
CN1933838A (zh) 2004-02-12 2007-03-21 默克公司 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺
JP4520991B2 (ja) * 2004-07-21 2010-08-11 三井化学アグロ株式会社 ジアミン誘導体、その製造方法およびそれらを有効成分とする殺菌剤
ES2326280T3 (es) * 2005-04-06 2009-10-06 F. Hoffmann-La Roche Ag Derivados de piridin-3-carboxamida como agonistas inversos de cb1.
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
WO2007011760A2 (fr) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibiteurs de la kinesine mitotique
EA015820B1 (ru) 2006-06-28 2011-12-30 Глэксо Груп Лимитед Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
BRPI0718515A2 (pt) * 2006-09-25 2013-11-19 Boehringer Ingelheim Int Compostos que modulam o receptor cb2
AU2007304363B2 (en) * 2006-10-04 2013-01-17 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as CB2 receptor modulators
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
SE535157C2 (sv) * 2010-07-14 2012-05-02 Fairchild Semiconductor Konduktivitetsmodulering i en bipolär transistor i kiselkarbid
WO2012031817A1 (fr) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Détermination des niveaux de protéine abca1 dans des cellules
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor

Also Published As

Publication number Publication date
CO6811864A2 (es) 2013-12-16
PT2718266T (pt) 2016-07-11
ES2588327T3 (es) 2016-11-02
HRP20180897T1 (hr) 2018-07-13
EA027247B1 (ru) 2017-07-31
HUE037666T2 (hu) 2018-09-28
JP6349360B2 (ja) 2018-06-27
ECSP13013074A (es) 2014-01-31
CR20130616A (es) 2018-01-26
JP2018150367A (ja) 2018-09-27
LT3072886T (lt) 2018-07-10
JP5997265B2 (ja) 2016-09-28
EP2718266A1 (fr) 2014-04-16
EP2718266B1 (fr) 2016-05-25
IL229685B (en) 2018-02-28
WO2012168350A1 (fr) 2012-12-13
HRP20161064T1 (hr) 2016-10-21
PE20180037A1 (es) 2018-01-09
NZ617464A (en) 2016-01-29
CN103608332B (zh) 2016-09-28
AU2017200801B2 (en) 2018-11-22
CL2013003486A1 (es) 2014-11-03
PE20141583A1 (es) 2014-10-25
CN103608332A (zh) 2014-02-26
EA023287B1 (ru) 2016-05-31
EA201391822A1 (ru) 2014-05-30
PL2718266T3 (pl) 2016-11-30
RS57262B1 (sr) 2018-08-31
HRP20161064T2 (hr) 2017-02-24
IL229685A0 (en) 2014-01-30
JP2017031162A (ja) 2017-02-09
MX2013014564A (es) 2014-03-21
PL3072886T3 (pl) 2018-08-31
UA114087C2 (xx) 2017-04-25
HK1231465A1 (zh) 2017-12-22
IL256826B (en) 2018-08-30
MX339992B (es) 2016-06-21
JP6484746B2 (ja) 2019-03-13
KR20140042848A (ko) 2014-04-07
SI3072886T1 (en) 2018-07-31
ES2588327T9 (es) 2017-02-21
CA2835745A1 (fr) 2012-12-13
AU2012266369A1 (en) 2013-11-21
US20160137606A1 (en) 2016-05-19
RS55073B1 (sr) 2016-12-30
AU2012266369B2 (en) 2016-11-10
SI2718266T1 (sl) 2016-08-31
RS55073B9 (sr) 2019-07-31
BR112013031463A2 (pt) 2016-12-06
US20120316147A1 (en) 2012-12-13
AU2017200801A1 (en) 2017-03-02
EP3072886B1 (fr) 2018-04-18
MY184978A (en) 2021-04-30
EA201591527A1 (ru) 2016-04-29
PT3072886T (pt) 2018-06-12
DK2718266T3 (en) 2016-06-13
TR201808273T4 (tr) 2018-07-23
CN106349156B (zh) 2018-12-11
US9321727B2 (en) 2016-04-26
CY1117878T1 (el) 2017-05-17
EP2718266B9 (fr) 2016-11-30
CN106349156A (zh) 2017-01-25
PH12016501375A1 (en) 2017-12-11
DK3072886T3 (en) 2018-06-25
NZ715284A (en) 2017-06-30
HUE027669T2 (en) 2016-11-28
EP3072886A1 (fr) 2016-09-28
SG10201604687QA (en) 2016-07-28
AR086881A1 (es) 2014-01-29
TWI567062B (zh) 2017-01-21
TW201311645A (zh) 2013-03-16
ES2673614T3 (es) 2018-06-25
JP2014516071A (ja) 2014-07-07

Similar Documents

Publication Publication Date Title
MA35245B1 (fr) Pyridin-2-amides utiles comme agonistes de cb2
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
MA35357B1 (fr) Composes de type anilines
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
CR20130369A (es) Novedosos derivados heterocíclicos
CR20140042A (es) Indazoles
IN2014MN02496A (fr)
MA35086B1 (fr) Compose de triazolopyridine
BR112013002182A2 (pt) derivados de quinolina e inibidores de melk contendo os mesmos
RS54207B1 (en) CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
CR20140237A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA35049B1 (fr) Triazolopyridines
CR20130419A (es) Derivados heterocíclicos de amina
EA201590854A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
ME00928B (me) Novi postupak za sintezu agomelatina
IN2015DN03145A (fr)
CR20140094A (es) Derivados de etinilo
MA37686B1 (fr) Composés phénoxyéthyl pipéridine
CR20140322A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2